Techno-Economic Evaluation of Novel SARS-CoV-2 Vaccine Manufacturing in the Insect Cell Baculovirus Platform

The need to increase the COVID-19 vaccine manufacturing capacity at low middle-income countries (LMIC) led a growing focus on Novavax (NVX-CoV2373), thermostable protein subunit manufactured using baculovirus and insect cell system (BICS) platform. This study aimed conduct techno-economic analysis assess BICS platform of compare it mRNA saRNA data from patent for formulation steps were used simulate production in SuperPro Designer. From analysis, productivity all platforms was compared terms doses/day per L scale. platform’s is about 1,000-fold 20-fold feasible option LMIC produce vaccines because cost dose like platform, while 7 times higher than platforms. However, further optimization necessary improve match saRNA’s